Controlled Access Programme (CAP) for the Republic of Ireland
As part of the conditions of Marketing Authorisation, the Marketing Authorisation Holder (UCB (Pharma) Ireland Ltd) is required to implement a controlled access programme (CAP).
A controlled access programme has been created to:
- prevent off-label use in weight management
- confirm that prescribing physicians have been informed of the need for periodic cardiac monitoring in patients taking Finteplaâ–¼ (fenfluramine).
IMPORTANT
In order for Fintepla prescriptions to be fulfilled through the High Tech Hub it is mandatory that each prescriber must complete this registration process. Failure to do this will mean the prescriber cannot be validated to prescribe through the High Tech Hub.
Follow the steps below to obtain your unique Prescriber ID:
- Complete form with your professional details
- Read the educational content & attest (approx. 2 mins)
- Receive & Save Your Prescriber ID
- Notification that your name has been approved through the High Tech Hub and you can prescribe Fintepla
Click below to download materials